- Home
- INSM vs CBRE Comparison
INSM vs CBRE Comparison
Compare INSM & CBRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- CBRE
- Stock Information
- Founded
- INSM 1988
- CBRE 1906
- Country
- INSM United States
- CBRE United States
- Employees
- INSM N/A
- CBRE N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- CBRE Real Estate
- Sector
- INSM Health Care
- CBRE Finance
- Exchange
- INSM Nasdaq
- CBRE Nasdaq
- Market Cap
- INSM 41.2B
- CBRE 47.0B
- IPO Year
- INSM 2000
- CBRE 2004
- Fundamental
- Price
- INSM $206.24
- CBRE $163.08
- Analyst Decision
- INSM Strong Buy
- CBRE Buy
- Analyst Count
- INSM 19
- CBRE 9
- Target Price
- INSM $173.35
- CBRE $171.89
- AVG Volume (30 Days)
- INSM 3.0M
- CBRE 1.4M
- Earning Date
- INSM 10-30-2025
- CBRE 10-23-2025
- Dividend Yield
- INSM N/A
- CBRE N/A
- EPS Growth
- INSM N/A
- CBRE 30.63
- EPS
- INSM N/A
- CBRE 4.05
- Revenue
- INSM $447,022,000.00
- CBRE $39,325,000,000.00
- Revenue This Year
- INSM $40.09
- CBRE $16.34
- Revenue Next Year
- INSM $129.64
- CBRE $9.39
- P/E Ratio
- INSM N/A
- CBRE $40.01
- Revenue Growth
- INSM 30.34
- CBRE 14.61
- 52 Week Low
- INSM $60.40
- CBRE $108.45
- 52 Week High
- INSM $209.77
- CBRE $171.00
- Technical
- Relative Strength Index (RSI)
- INSM 70.57
- CBRE 65.29
- Support Level
- INSM $194.65
- CBRE $148.76
- Resistance Level
- INSM $209.77
- CBRE $156.95
- Average True Range (ATR)
- INSM 6.85
- CBRE 3.63
- MACD
- INSM 0.15
- CBRE 1.33
- Stochastic Oscillator
- INSM 86.77
- CBRE 93.77
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.